556
Participants
Start Date
April 17, 2022
Primary Completion Date
June 30, 2027
Study Completion Date
June 30, 2029
PD-1 antibody
Tislelizumab：200 mg per dose, intravenous infusion over 30 minutes, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy
Capecitabine
Capecitabine : 650 mg/m2 bid, orally, d1-21, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy
RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
Tongji Hospital
OTHER
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER
Xiangya Hospital of Central South University
OTHER
Affiliated Cancer Hospital of Guizhou Medical University
UNKNOWN
Cancer Hospital of Guangxi Medical University
OTHER
First People's Hospital of Foshan
OTHER
Chongqing University Cancer Hospital
OTHER
Hubei Cancer Hospital
OTHER
Hunan Cancer Hospital
OTHER
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
OTHER
Fifth Affiliated Hospital, Sun Yat-Sen University
OTHER
Shandong Provincial Hospital
OTHER_GOV
Sun Yat-sen University
OTHER